Coagulation Factors & mAbs recombinant coagulation factor therapies and targeted monoclonal antibodies address bleeding disorders, oncological conditions, and inflammatory diseases. Our Aryogen portfolio delivers high-quality biologics with proven clinical profiles to patients across the region.

-Haemophilia & Bleeding Disorders
-Anti-CD20 Targeted Therapy
-Anti-VEGF Treatment
-TNF-α Modulation
-Recombinant Factor VIII Therapy
-Anti-HER2 Oncology
-IL-6 Pathway Inhibition
-Type 2 Inflammation / Atopic Disease

Coagulation Factors & mAbs